| Literature DB >> 21878046 |
Jan Otto Beitnes1, Ketil Lunde, Jan E Brinchmann, Svend Aakhus.
Abstract
Despite recent advances in medical therapy, reperfusion strategies, implantable cardioverter-defibrillators and cardiac assist devices, ischemic heart disease is a frequent cause of morbidity and mortality worldwide. Cell therapy has been introduced as a new treatment modality to regenerate lost cardiomyocytes. At present, several cell types seem to improve left ventricular function in animal models as well as in humans, but evidence for true generation of new myocardium is confined to the experimental models. In the clinical perspective, myocardial regeneration has been replaced by myocardial repair, as other mechanisms seem to be involved. Clinical studies on adult stem cells suggest, at best, moderate beneficial effects on surrogate end points, but some applications may qualify for evaluation in larger trials. Complete regeneration of the myocardium by cell therapy after a large myocardial infarction is still visionary, but pluripotent stem cells and tissue engineering are important tools to solve the puzzle.Entities:
Mesh:
Year: 2011 PMID: 21878046 DOI: 10.1586/erc.11.108
Source DB: PubMed Journal: Expert Rev Cardiovasc Ther ISSN: 1477-9072